From pig kidney transplants to the development of a new schizophrenia drug, here are five of the biggest medical ...

This year saw lofty highs and devastating lows for neuroscience drug developers like Bristol Myers Squibb, Eli Lilly and ...

BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely ...

schizophrenia treatment market is expected to expand globally by enhancing existing treatments and improving patient care.

Makary will “restore FDA to the Gold Standard of Scientific Research, and cut the bureaucratic red tape at the Agency to make sure Americans get the Medical Cures and Treatments they deserve ...

We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...

The data analytics and consulting company valued the market at $8.4 billion in 2021. The forecasted 7.4% compound annual ...

As 2024 comes to an end, it is crucial to take a look at some of the major medical advancements that happened this year. 2024 ...

There are always new frontiers in health care: diseases whose treatment and cures still elude us; biological and medical ...

(USA Today) In an exploratory analysis of two phase III trials, xanomeline/trospium chloride (Cobenfy) improved cognition in ...

Bristol Myers Squibb’s Cobenfy is the first treatment in seven decades that does not modulate dopaminergic or serotonergic ...

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. | In ...